[Acute hepatitis C in 2005].
There have been numerous new data in the field of acute hepatitis C in the past few years. The goal of this study was to gather recent results in the literature to determine the best current therapeutic strategy of acute hepatitis C. Epidemiology has made enormous progress with the disappearance of acute post transfusion hepatitis C. Infection by intravenous drug-addiction has became prevalent, and nosocomial and sexual modes of transmissions are now seen. At the same time, the average age of the infected patients has dropped by 13 years, and the proportion of acute forms with a spontaneously favourable outcome have increased compared to the period before 1995. Understanding of the predictive factors of cure have become important, particularly not to treat acute hepatitis C which will have a spontaneously favorable outcome. Waiting from 8 to 12 weeks after jaundice or symptomatic forms is recommended. The decision to treat must be made in the first 6 months, since the results are better compared to a late and longer treatment. Monotherapy by pegylated interferon for 6 months ensures more than 90% of sustained viral response. Shorter treatment is possible but high daily doses of interferon are necessary, reducing tolerance. Finally bi therapy with a interferon and ribavirin is not beneficial
Nguyen-Khac
Eric
E
Service d'Hépato-Gastroentérologie, CHU d'Amiens, Place Victor Pauchet, 80054 Amiens Cedex 1. nguyen-khac.eric@chu-amiens.fr
D000208:Acute Disease; D000998:Antiviral Agents / Q000627:therapeutic use*; D006526:Hepatitis C / Q000188:drug therapy* / Q000453:epidemiology* / Q000635:transmission; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010347:Patient Care Planning; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D015995:Prevalence; D011379:Prognosis; D011994:Recombinant Proteins; D012307:Risk Factors; D015819:Substance Abuse, Intravenous; D013997:Time Factors
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C100416:peginterferon alfa-2a